alendronate has been researched along with Gastric Diseases in 3 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate (10 mg daily) has been shown in long term clinical trials to be an effective treatment for postmenopausal osteoporosis." | 5.10 | The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. ( Daifotis, A; Lanza, F; Leung, A; Musliner, T; Quan, H; Reyes, R; Sahba, B; Schwartz, H; Torosis, J; Winograd, S, 2002) |
| "Alendronate use was not associated with a significant increase in upper GI tract events among women at increased risk for these events (those aged > or =75 years with previous upper GI tract disease or using nonsteroidal anti-inflammatory drugs)." | 2.69 | Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. ( Bauer, DC; Black, D; Ensrud, K; Freedholm, D; Hochberg, M; Musliner, T; Nevitt, M; Thompson, D, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nicolau, LA | 1 |
| Silva, RO | 1 |
| Damasceno, SR | 1 |
| Carvalho, NS | 1 |
| Costa, NR | 1 |
| Aragão, KS | 1 |
| Barbosa, AL | 1 |
| Soares, PM | 1 |
| Souza, MH | 1 |
| Medeiros, JV | 1 |
| Bauer, DC | 1 |
| Black, D | 1 |
| Ensrud, K | 1 |
| Thompson, D | 1 |
| Hochberg, M | 1 |
| Nevitt, M | 1 |
| Musliner, T | 2 |
| Freedholm, D | 1 |
| Lanza, F | 1 |
| Sahba, B | 1 |
| Schwartz, H | 1 |
| Winograd, S | 1 |
| Torosis, J | 1 |
| Quan, H | 1 |
| Reyes, R | 1 |
| Daifotis, A | 1 |
| Leung, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial[NCT00398931] | Phase 3 | 1,099 participants (Actual) | Interventional | 1998-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for alendronate and Gastric Diseases
| Article | Year |
|---|---|
Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Digestive System; Double-Blind Method; Duodenal | 2000 |
The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.
Topics: Administration, Oral; Adult; Aged; Alendronate; Confidence Intervals; Dose-Response Relationship, Dr | 2002 |
1 other study available for alendronate and Gastric Diseases
| Article | Year |
|---|---|
The hydrogen sulfide donor, Lawesson's reagent, prevents alendronate-induced gastric damage in rats.
Topics: Alendronate; Analysis of Variance; Animals; Cystathionine gamma-Lyase; Diagnosis, Computer-Assisted; | 2013 |